Chi-Mei Medical Center, Liouying

Tainan 73657

0 studies enrolling now · 11 studies all time

What they study most

AML Arising From Myelodysplastic Syndrome (MDS), Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small-Cell Lung, Diffuse Large B-cell Lymphoma, Follicular Lymphoma (FL), Head and Neck Cancer, Hepatocellular Carcinoma, Leukemia, Myeloid, Acute, Locally Recurrent Breast Cancer, Marginal Zone Lymphoma, Metastatic Breast Cancer, Newly Diagnosed Acute Myeloid Leukemia (AML)

Studies at this site

• Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Running, not enrolling
• Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL — Running, not enrolling
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation — Running, not enrolling
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC — Completed
• Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) — Stopped early
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) — Stopped early
• Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer — Stopped early
• Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma — Completed
• Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) — Stopped early